翰思艾泰-B12月15日至12月18日招股 预计12月23日上市

Core Viewpoint - The company, Hansai Aitai-B (03378), is set to launch an initial public offering (IPO) from December 15 to December 18, 2025, aiming to issue 18.32 million shares at a price range of HKD 28-32 per share, with trading expected to commence on December 23, 2025 [1] Group 1: Company Overview - The company specializes in biotechnology with expertise in structural biology, translational medicine, and clinical development, having developed a product pipeline since 2016 that includes one core product and nine other candidates [1] - The core product, HX009, is a self-developed anti-PD-1/SIRPα dual-function antibody fusion protein, currently undergoing multiple clinical trials in China for various cancer treatments [2][3] Group 2: Product Pipeline - The company has two additional major products, HX301 and HX044, both in clinical stages targeting cancer treatment, with HX301 being a multi-target kinase inhibitor and HX044 a novel dual-function anti-CTLA-4 antibody SIRPα fusion protein [3] - HX301 has completed Phase I clinical trials and is currently in a Phase II trial in China for glioblastoma treatment, while HX044 is in I/IIa phase trials for advanced solid tumors [3] Group 3: Funding and Use of Proceeds - The company has entered cornerstone investment agreements with several investors, agreeing to subscribe for a total of approximately 2.9178 million shares at the maximum offer price of HKD 32.00 per share [4] - The estimated net proceeds from the global offering, assuming a median offer price of HKD 30.00 per share, is approximately HKD 496 million, with planned allocations of 35% for HX009 development, 33% for HX301 and HX044, 17% for other important products, 5% for commercialization and business development, and 10% for working capital and general corporate purposes [5]